Three clinical trials started at the Medical University of Vienna
Commissioned by multinational pharmaceutical firms
Vienna, 30 March 2010 The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct
three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel.
Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation.
The team will investigate the use of the monoclonal antibody ipilimumab as part of the immunotherapeutic treatment. This antibody can cause the body's own immune system to react against cancer cells. Prof. Krainer said that